Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6101934rdf:typepubmed:Citationlld:pubmed
pubmed-article:6101934lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C0002962lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C0585361lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C1549485lld:lifeskim
pubmed-article:6101934lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:6101934pubmed:issue2lld:pubmed
pubmed-article:6101934pubmed:dateCreated1980-4-17lld:pubmed
pubmed-article:6101934pubmed:abstractTextThe effects of five beta-adrenoreceptor blocking agents and placebo during twice daily sustained therapy were compared in 23 patients with stable, exertional angina pectoris. The study was double blind in design, and each drug was prescribed for a period of one month in a random fashion. The number of anginal attacks and consumption of glyceryl trinitrate tablets during the one month period were significantly reduced by a similar degree during therapy with all five beta blocking drugs in comparison to the placebo (P less than 0.01). Exercise tolerance, when assessed 12 hours after a previous dose had been given and 1 hour after the morning dose was given, also improved by a similar degree with all five drugs in comparison to the placebo (P less than 0.01). The increase in exercise duration was associated with a significant reduction in the S-T segment depression, heart rate, systolic blood pressure, and the product of heart rate and systolic blood pressure, with each of the five drugs--effects markedly different from those obtained with the placebo (P less than 0.01). These data show that noncardioselective (propranolol and oxprenolol) and cardioselective (practolol, metoprolol and tolamolol) agents, as well as drugs with intrinsic sympathomimetic activity (oxprenolol and practolol), were equally effective antianginal agents during sustained therapy. Furthermore, twice daily therapy with any of these drugs was effective in the management of patients with angina pectoris.lld:pubmed
pubmed-article:6101934pubmed:languageenglld:pubmed
pubmed-article:6101934pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6101934pubmed:statusMEDLINElld:pubmed
pubmed-article:6101934pubmed:monthFeblld:pubmed
pubmed-article:6101934pubmed:issn0002-9343lld:pubmed
pubmed-article:6101934pubmed:authorpubmed-author:DavidsonCClld:pubmed
pubmed-article:6101934pubmed:authorpubmed-author:TaylorS HSHlld:pubmed
pubmed-article:6101934pubmed:authorpubmed-author:ThadaniUUlld:pubmed
pubmed-article:6101934pubmed:authorpubmed-author:SingletonWWlld:pubmed
pubmed-article:6101934pubmed:issnTypePrintlld:pubmed
pubmed-article:6101934pubmed:volume68lld:pubmed
pubmed-article:6101934pubmed:ownerNLMlld:pubmed
pubmed-article:6101934pubmed:authorsCompleteYlld:pubmed
pubmed-article:6101934pubmed:pagination243-50lld:pubmed
pubmed-article:6101934pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:meshHeadingpubmed-meshheading:6101934-...lld:pubmed
pubmed-article:6101934pubmed:year1980lld:pubmed
pubmed-article:6101934pubmed:articleTitleComparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris.lld:pubmed
pubmed-article:6101934pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6101934pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6101934pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6101934pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6101934lld:pubmed